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Abstract
Background: The incidence of epilepsy is greatest in the first 2 years of life, an age group where there is generally a
poor prognosis for both seizure control and neurodevelopmental outcome. Early control of seizures can be associated
with better developmental outcome but many of the epilepsies presenting in infancy are poorly responsive to
antiepileptic medication. The ketogenic diet (KD) is a high-fat, low-carbohydrate diet designed to mimic the effects of
starvation on the body. Dietary fat is converted into ketones in the body and used as an energy source by the brain.
The KD has been shown to be successful in controlling seizures in many observational studies, and in two randomised
controlled trials (RCTs) in older children. However, little evidence is available in the very young.
Methods/design: An open-label RCT where eligible children (age 3 months to 2 years with epilepsy who have failed
two antiepileptic drugs (AEDs)) undergo baseline assessment, including medical and seizure history. Participants then
start an observation period (7 or 14 days) with documentation of seizure frequency. Randomisation will occur on day 8
or day 15 to receive the KD or a further AED; the allocated treatment will commence on day 15, with instruction and
training. A second assessment (4 weeks after start of treatment) will include a clinical review and tolerability
questionnaire (modified Hague Scale of Side Effects – for those allocated to the KD group). Assessments will be
repeated at 8 weeks after the start of treatment including biochemical investigations, after which, according to patient
response, KD (diet group) or AED (standard AED group) will then be continued or changed. Those in the AED group
who have failed to achieve seizure control at the 8-week assessment will then be offered KD outside the context of the
trial. Those in the KD arm who fail to achieve seizure control will be changed to standard clinical management. All
patients will be followed up for 12 months from randomisation for retention, seizure outcome, quality of life and
neurodevelopmental status.
Discussion: The slow rate of recruitment is an ongoing practical issue. There is a limitation to the number of eligible
patients compared to what was predicted, mainly due to the nature of this patient group. After a substantial
amendment to widen inclusion criteria and reduce the baseline period to 7 days for patients with a high seizure
burden, the rate of recruitment steadily increased. A number of operational concerns regarding dietetic time were also
highlighted impacting on the recruitment rate. However, the combination of a low dropout rate and the opening of
further centres, the trial should successfully meet the final recruitment target. All nine centres are now recruiting and
we hope to open further centres within the UK.
Trial registration: ClinicalTrials.gov, identifier: NCT02205931. Registered on 16 December 2013.
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Background
Epilepsy is a condition whereby individuals are prone to
recurrent epileptic seizures, a change in behaviour or
movement that is the direct result of a primary change
in the electrical activity in the brain. It is not a single
condition – there are many different underlying causes
and, more accurately, they should be referred to as the
epilepsies. Up to 65% of individuals with epilepsy will
have seizures controlled with antiepileptic drugs (AEDs)
or enter spontaneous remission in their lifetime [1].
However, this leaves 35% who will continue with sei-
zures despite treatment. Standard first-line management
of an individual presenting with epilepsy is antiepileptic
medication, decided on the basis of the type of epilepsy.
Although guidelines exist on which drug to use, manage-
ment is still based on a ‘trial and error’ approach [2].
When the type of epilepsy or seizure is unclear, it can be
difficult to optimise treatment at the outset.
The incidence of epilepsy is greatest in the first 2 years
of life (56–88/100,000 children/year), [3] a population
who remain most at risk for neurodevelopmental com-
promise in the longer term. Early control of seizures is as-
sociated with better developmental outcome [4] but,
unfortunately, many of the epilepsies presenting in infancy
are associated with a poor prognosis for seizure control [5,
6]. Little evidence is available with regard to effective
treatments and, even where seizure freedom is achieved,
this is unlikely to be sustained long term [7]. This group
of children place a large burden on health services, with a
need for regular clinical review and ongoing medication,
as well as clinical and therapy support. This is especially
true for those who remain resistant to medication, this
group being amongst the most costly for medical and care
services long term. It is, therefore, imperative that all other
treatment options are explored as early as possible [8].
The epilepsies in this age group also remain poorly de-
fined entities; very few can be classified into an epilepsy
syndrome and diagnosis of underlying cause remains
difficult. Over 50% of infants presenting with seizures
will have infantile spasms [3]. This affects approximately
1 in 2000 infants. First-line treatment options (cortico-
steroids or vigabatrin) lead to seizure freedom in up to
70% of cases [9] but side effects limit their duration of
use and relapse rates are substantial (40%) [10]. Further,
those who fail these treatments are limited in their treat-
ment options. Of the remaining types of epilepsy, the
majority are resistant to medication. There is little evi-
dence on which to base our decisions on specific AED
use in this young age group. Epidemiological data have
shown this group to be the least likely to achieve longer-
term remission of up to 2 years [11].
The ketogenic diet (KD) is a high-fat, low-carbohydrate
diet designed to mimic the effects of starvation on the
body. The main energy intake is fat, which is converted to
ketones in the body and used as an energy source. The
classical KD is based on an intake of long-chain fat,
usually in a ratio of 3 or 4 g of fat to 1 g of carbohydrate
and protein. The medium-chain triglyceride (MCT) KD
utilises MCT fat, which generates more ketones per cal-
orie compared to long-chain fat, theoretically allowing
greater dietary intake of carbohydrate. More liberal diets
have also been utilised, including the Modified Atkins Diet
and low-glycaemic-index treatment, which are high in fat,
low in carbohydrate but with unlimited protein [12, 13].
The KD has been shown to be successful in control-
ling seizures in many observational studies [14, 15].
However, there is limited evidence examining efficacy
against no change or alternative treatments from rando-
mised controlled trials (RCTs) [16]. The first RCT of the
KD to demonstrate effectiveness in children aged 2–16
years was published in 2008 [17]. In this trial, 145 children
aged 2–16 years, who had failed at least two AEDs and
had at least seven seizures weekly, were randomised to re-
ceive a KD, either immediately or after a 3-month delay
with no additional treatment changes (the latter being the
control group). After 3 months, the mean percentage of
baseline seizures (on an intention-to-treat analysis) was
significantly lower in the diet group (62%) than in controls
(137%, p < 0.0001). Twenty-eight (38%) of the diet group
had greater than 50% seizure reduction, compared to four
(6%) controls (p < 0.0001). One further RCT of similar de-
sign and in the same age group has been reported demon-
strating efficacy of the Modified Atkins Diet to a similar
degree [13]. There has been no RCT assessing treatment
with the KD in children under the age of 2 years.
Open-label, observational evidence indicates that the
KD could be particularly effective in younger children.
Open-label studies have suggested it to be an effective
and well-tolerated treatment for infants [12, 18–26].
One study reported significant improvements in infantile
spasms and fewer side effects when the diet was used as
an alternative first-line therapy to adrenocorticotrophic
hormone (ACTH) [27].
The mechanism of action of the KD is not yet known.
Recent evidence suggests that medium-chain fatty acids,
more specifically decanoic acid, may have a specific role in
its antiepileptic effect [28–30]. These data raise the possi-
bility that C10 alone has the ability to mimic aspects of
the KD. Whether this has a role in a possibly enhanced
action of the KD in infancy should be determined and the
biochemical basis for effectiveness identified [31, 32].
The KD is a high-resource treatment, requiring patient-
specific calculation and regular input from a specialist
paediatrician and dietitian, with close monitoring there-
after. It also requires diligence on the part of the families.
It is also not without side effects. It is imperative that the
effectiveness and safety of the KD in this very young age
group is now studied in a well-designed clinical trial.
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Study objectives
The primary objective is to assess the effectiveness of the
KD compared to AEDs in the treatment of infants with
epilepsy aged 3 months to 2 years of age who continue to
have seizures despite previous trials of two AEDs. The sec-
ondary objectives are to determine tolerability of the KD
relative to standard AEDs, adherence to treatment over
time, the effect on quality of life and neurobehavioural
progress. Further, we aim to estimate whether the pres-
ence of medium-chain fatty acids in the context of use of
the KD is associated with seizure control.
Methods/design
The project proposed is an open-label, randomised con-
trolled, multicentre clinical trial of children aged 3
months to 2 years of age with epilepsy who have failed
to respond to two or more pharmacological treatments
(AED or corticosteroids), comparing KD to further AED
treatment. The study will be conducted in two phases:
first, we will carry out a pilot phase in two centres. If the
pilot study recruits successfully, we will proceed to the
full trial in a further seven centres. See Additional file 1
for a schematic of the trial design.
Eligible children will be consented via their parents.
They will undergo baseline assessment including medical
and seizure history, neurological and anthropometric
examination, administration of quality of life (Infant and
Toddler Quality of Life Questionnaire, [33]) and develop-
mental (Vineland Adaptive Behaviour Questionnaire,
[34]) questionnaires and biochemical investigations.
They will then start a 2-week observation period with
documentation of seizure frequency. If the child is
prone to particularly frequent seizures in excess of
two per day, then a minimum baseline period of 1
week would be considered sufficient. Food diaries re-
quired for diet calculation will be returned by post
from all enrolled infants 1 week (or sooner for those
with an unstable clinical condition) into the observation
period. Standardised seizure records will be kept during
the observation period and throughout the trial. Random-
isation will be conducted using an Internet randomisation
system provided by Sealed Envelope™ (Sealed Envelope
Ltd.). Randomisation will occur on day 8 or day 15 for
participants to receive the KD or a further AED; the allo-
cated treatment will commence following randomisation,
with instruction and training.
The randomisation schedule will be independently gen-
erated and held by Sealed Envelope™. Allocations will be
released by email to the coordinating centres once the in-
vestigator or research nurse has entered eligible partici-
pant information into the web-based randomisation
service. Participants will be allocated to either the KD or
further AED arm using a simple, concealed, randomisa-
tion method. Randomisation will aim to achieve 92 in the
KD group versus 68 participants in the further AED arm
(see calculation in ‘Sample size’ section). An Enrollment
Log will be maintained to keep records of the screened
and randomised patients at each site. Withdrawn patients
will not be replaced and replacement numbers will not be
issued. Whilst it will not be possible to blind participants
to their treatment allocation, efforts will be made to min-
imise expectation bias by emphasising in the trial litera-
ture that the evidence supporting the KD for seizure
control is currently limited.
A second assessment (4 weeks after start of treat-
ment) will include clinical review and a tolerability
questionnaire (modified Hague Scale of Side Effects –
see Additional file 2). Assessments will be repeated at
8 weeks after the start of treatment including clinical
review, administration of the Infant and Toddler
Quality of Life Questionnaire, the tolerability ques-
tionnaire, and biochemical investigations. After the
8-week assessment, according to patient’s clinical re-
sponse to treatment with regards seizure outcome
and tolerability, the KD (diet group) or AED (stand-
ard AED group) will then be continued or changed.
Those in the AED group who have failed to achieve
seizure control at the 8-week assessment will then be
offered the KD outside the context of the trial. Those
on the KD who have failed to achieve seizure im-
provement at the 8-week assessment will continue
with medical management, as per clinician decision.
All participants will be followed up for 12 months
following randomisation for retention, seizure out-
come and neurodevelopmental status. See Fig. 1
(Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) figure: schedule of enroll-
ment, interventions and assessments) and Additional
file 3 for the SPIRIT 2013 Checklist (recommended
items to address in a clinical trial protocol and re-
lated documents).
At each of the centres, the paediatric neurologist will
work with a dietitian for KD implementation. Treatment
will be in accordance with the KD Intervention Manual,
which will be agreed with reference to a standard text
[35] and discussed with the project management team at
the outset during the initial workshop to enable stand-
ardisation of treatment between different centres. There
will be an AED consensus flowchart (Additional file 4)
for guidance regarding management of the participant’s
epilepsy, written following an initial workshop with
paediatric neurologists from all nine centres; this flow-
chart will be used to create a standardised manual (AED
Consensus Document).
Selection of participants
Children aged 3 months to 2 years with an established
diagnosis of epilepsy, who continue to have epileptic
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seizures despite treatment with two AEDs, will be
screened for entry into the trial. Recruitment will be from
hospital-based paediatric neurology centres, with the add-
itional involvement of a user group, Matthew’s Friends
Charity, an organisation set up to raise awareness and
availability of the KD in the UK, and which now also sup-
ports clinics implementing the KD. Many, if not all of the
suitable patients will already be under the care of tertiary
paediatric neurology centres according to National Guide-
lines (https://www.nice.org.uk/guidance/cg137).
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure; schedule of enrollment, interventions and assessments.
*At baseline, all procedures should be done before randomisation. **Ketogenic diet group only. (X) – As indicated/appropriate. 1Complete
physical includes weight, length, head circumference, general examination. 2Tests to be done: haematology – full blood count (FBC);
biochemistry – liver function tests, renal function tests, calcium, urate, glucose, phosphate, vitamin D, selenium, zinc, cholesterol, carnitine profile
and beta-hydroxybutyrate; urinalysis – organic acids, urine calcium and creatinine ratio. Results must be received prior to randomisation. 3Home
monitoring urine dipstick and blood spot ketones done twice a day and recorded in Seizure Diary (only KD arm). 4Special assay or procedure –
blood sample to be analysed by Simon Heales at ICH
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Inclusion criteria
1. Age between 3 months and 24 months of age
(not beyond second birthday at baseline)
2. Diagnosis of epilepsy confirmed
3. Seizure frequency greater than or equal to four
seizures/week on average in the baseline period
4. Failed response to previous trial of two antiepileptic
drugs. In the case of infantile spasms, this could
include a trial of corticosteroids
5. Children with written informed consent from a
parent/guardian
Exclusion criteria
1. Continues on corticosteroids less than 2 weeks prior
to randomisation
2. Metabolic disease contraindicating use of the KD, e.g.
pyruvate carboxylase deficiency, medium-chain acyl-
CoA dehydrogenase (MCAD) deficiency from previ-
ous medical investigation and screening at baseline
3. Progressive neurological disease
4. Severe gastroesophageal reflux
5. Previous treatment with the KD
6. Concurrent participation in another clinical trial of
an investigational medicinal product (IMP)
7. Patients who are prescribed AEDs not listed in the
trial IMPs
8. Patients who have a listed contraindication as per
the Summary of Product Characteristics (SmPC) to
any of the AEDs listed in the trial IMPs
Sample size
For the primary outcome variable, based on data from
Neal et al., [17], we used mean percentage change in
seizures from baseline of 62% (SD 45) in the KD group,
assuming a change of 90% in the control group (SD 50)
(100 = no change in frequency of seizures from baseline)
at 90% power and 5% significance. This gives a sample size
of 61 in each group (122 in total). Accounting for a 10%
dropout rate, gives 68 in each group (136 in total), and in-
flation for a therapist effect (dietitian) to one group, as-
suming nine centres, with an average cluster size of eight
and an intracluster correlation coefficient (ICC) of 0.05,
the inflation factor is 1.35, giving 92 in the KD group and
68 in the control group (160 in total). If dropout was 20%,
this sample size would still have 86% power.
Treatment procedures
Trial arm 1 Classical ketogenic diet (KD arm)
The experimental intervention will be an 8-week trial
of KD therapy. A KD intervention manual will be
created and provided to sites to ensure consistency of
the KD implementation across centres. The manual in-
cludes basic instructions on how to calculate the clas-
sical KD and advice regarding diet implementation such
as supplementation, tube feeding, breastfeeding, weaning
and fine-tuning the diet. Children allocated to KD ther-
apy will have their diets individually calculated by a
paediatric dietitian with consideration of daily calorie re-
quirements, adequate protein intake for growth and vita-
min and mineral supplementation. All diets will be
implemented according to a classical KD protocol, i.e.
based on a ratio of fat to carbohydrate and protein that
will usually be between 2:1 and 4:1. In order to achieve a
state of ketosis, meal plans have to be accurately calcu-
lated for each child individually and recorded in the pa-
tient’s medical notes. Breastfeeding can be continued on
a KD, in combination with a ketogenic feed which will
be given in a prescribed amount before each breastfeed.
If breast milk is expressed, this can be mixed with the
ketogenic feed to the correct macronutrient ratio. In-
fants on a KD can be weaned as per Department of
Health guidelines [36], with advice given on how to
adapt standard weaning foods by addition of extra fat.
Hospital stays will be determined by the clinical team at
the treating centre, utilising the ‘Trial Intervention Manual’.
A non-fasting initiation protocol will be used for all chil-
dren. Parents or carers will attend a teaching session prior
to diet commencement, including how to manage possible
early side effects, such as excess ketosis and hypoglycaemia.
Teaching of families in the KD arm will occur following
randomisation and prior to starting the diet.
The KD to be implemented will be the classical KD,
aiming for at least a 3:1 ratio (fat to carbohydrate and
protein). This will be implemented according to a stand-
ard text [35]. Further, an initial workshop of dietitians will
be led by Elizabeth Neal (co-principal investigator (PI)) in
order to ensure consistency of implementation. Cross-site
consistency of KD implementation will be monitored after
the 8-week and 12-month visits by the dietetic assistant.
Details to be monitored include the calculation of energy
prescriptions, protein intake, teaching sessions, initiation
regimes, supplementation and ketone levels. Monitoring
Discrepancy Forms will be created and the Protocol Devi-
ation Log completed, if appropriate.
Trial arm 2 Further antiepileptic drugs (AED arm)
The control intervention will be drug therapy with the
most appropriate further AED for a particular child, de-
pending on their presenting seizures, epilepsy syndrome
and previous drugs used. This will be chosen by the expert
clinician responsible for management of the participant’s
epilepsy. Paediatric neurologists will meet at an initial work-
shop to discuss clinical practice with the aim of forming the
basis of a consensus protocol to ensure the consistency of
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AED treatments delivered. The list of agreed drugs that
may be utilised are described in Additional file 5. These are
considered IMPs in this trial, irrespective of which arm of
the trial the patient is randomised to. This is a pragmatic
trial that uses authorised medicinal products for epilepsy
within the European Economic Area (EEA). Although the
majority of these IMPs are not licensed for paediatric use,
or for use in this age group, they are used in routine care as
part of established clinical practice. Patients who are pre-
scribed products with no marketing authorisation (‘spe-
cials’) for epilepsy or AEDs not listed in the below table will
not be eligible for this trial. The KD is not classed as a me-
dicinal product and is not included in Additional file 5. The
dietetic assistant will monitor cross-site consistency of IMP
prescription according to the protocol.
A discussion about diet and healthy eating will be also be
undertaken with families of infants randomised to the
AED arm at the randomisation visit. If the participant is
already under local dietetic support, it should be ensured
that this monitoring continues. If the participant does not
have local dietetic support but this is deemed necessary by
the ketogenic dietitian, an appropriate referral should be
made by the clinician. Otherwise, a very brief discussion
about general infant or toddler nutrition will be had, in-
cluding details such as promotion of breastfeeding, age-
appropriate texture progression for weaning, food groups
and the important of iron-rich foods.
Statistical analysis
Analysis will be done by intention-to-treat. Baseline
characteristics of participants in the control and inter-
vention arms will be summarised. The primary outcome
will be seizure count in the final 2 weeks of the interven-
tion period and in the baseline assessment period. Data
will be analysed using a Poisson mixed model to account
for clustering by centre (synonymous with therapist).
The randomised allocation will be entered into the
model as a fixed effect as will an indicator of time point
(baseline or end of study), whilst the centre will be in-
cluded as a random effect. Analysis of secondary out-
comes (those seizure free and responders) will be
analysed using random-effects logistic models – centre
being the random effects and randomised group a fixed
effect. The process outcomes relating to tolerability and
medium-chain fatty acids in the KD group will be ana-
lysed using random-effects modelling. Therapist effects
will be investigated further in supportive analyses [7, 37].
Discontinuation/withdrawal of participants and ‘stopping
rules’
Participants will be withdrawn from the treatment prior to
8 weeks should there be over 50% increase in seizure fre-
quency from baseline or if side effects, such as diarrhoea
or constipation, are not resolved by dietary manipulation
or medication. Withdrawn patients will not be replaced,
but will have scheduled follow-up assessments.
Deliverability and feasibility
An initial pilot study involving two centres over 12
months will aim to recruit approximately 20% of the
total sample required: 35 participants over 12 months.
The pilot study will run in two centres in London: Great
Ormond Street Hospital for Children and Evelina London
Children’s Hospital over the initial 12 months. We will
aim to assess approximately 50 eligible patients in this
time frame. Additionally, adverse events (AEs) will be
monitored and data on safety will be reviewed. We will
progress to the full study if the following are achieved:
1. Achieving a 60% recruitment rate; 30 families
agreeing to randomisation
2. No more than 10 (29%) failing to complete the
8-week trial period
The main study will proceed to include recruitment
from the further seven centres should the above criteria
be met. Recruitment will be expected at a rate of 28/year
from GOSH, and approximately 7/year from the
remaining seven centres (total 84/year). This enables a
completed primary outcome in the desired 160 children.
Outcomes
The primary outcome will be the number of seizures
experienced during weeks 6–8 compared to the number
of seizures in the baseline period.
Secondary outcomes will include (at 8 weeks):
 Number of children seizure free
 Responder rate, defined as the number showing
more than a 50% improvement in seizure frequency
compared to baseline (taken as the mean daily
seizure frequency over the observation baseline
period immediately preceding the 8-week review)
 Tolerance to KD as assessed by side effect
questionnaire and blood results
 Relationship between medium-chain fatty acids and
seizure control
Secondary outcomes will also include (at 12 months):
 Retention on treatment (the number of participants
who remain on the KD, or the prescribed AED, at
12 months)
 Quality of life (as measured by the Infant Toddler
Quality of Life Questionnaire)
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 Neurodevelopmental outcome (as measured by the
Vineland Adaptive Behaviour Scales)
Plasma profiles of medium-chain fatty acids will be
evaluated at baseline and at 8 weeks. Assessment of
mitochondrial function (respiratory-chain enzymes) and
enrichment (citrate synthase) will be determined in
white cells and platelets. The effect of specific ratios of
medium-chain fatty acids, to mimic patient plasma pro-
files, upon neuronal mitochondrial function/enrichment
(biochemical plus electron microscopy studies) will be
documented. Additionally, such fatty acid profiles will be
studied, with regards to antiepileptic effect, in an estab-
lished in vitro (hippocampal slice) model.
Discussion
We summarise here the protocol of an open-label RCT,
designed to evaluate the effectiveness of the KD in chil-
dren with epilepsy under the age of 2 years who have
failed two AEDs, compared to standard AED treatment.
We hypothesise that the KD is more effective in reducing
seizure frequency in infants (age 3 months to 2 years) with
epilepsy who have failed to respond to two or more
pharmacological agents (AED or corticosteroids) com-
pared to conventional management with an AED.
There is genuine equipoise between the two treatment
groups. There is little evidence on the effectiveness of treat-
ments in children with epilepsy under 2 years of age, in par-
ticular comparative evidence. The most common seizure
type to present in infancy is infantile spasms, for which there
is evidence on first-line treatment [9]; there is no RCT-
derived evidence on which treatment to use should either
steroids or vigabatrin fail. Further, there is little evidence in
other seizure types or syndromes in this age group. There is,
therefore, a need to determine whether KD treatment or
standard drug treatment should be utilised early in the nat-
ural history of the condition. Information on the effective-
ness of the KD in the treatment of younger children is
limited to the results of open-label, non-randomised and
non-prospective studies. Further, numbers are small, chil-
dren are reported only at the severe end of the spectrum
and, in some, the diet is trialled in preference to conven-
tional antiepileptic medication known to be beneficial [27].
The results from the trial in the older children [17], although
still showing the diet to be effective, did not show this to the
same degree as in the reported open studies. It is important
to determine the place of the KD in this younger group of
patients, both with regard to effectiveness and safety, consid-
ering the resource required and vulnerability of the group.
Some concern could be expressed about the duration of
the trial at only 8 weeks to primary outcome; many studies
utilise a 3-month assessment period, and the KD can take
a while to introduce and fine tune. In the group of
children to be assessed, namely children under the age of
2 years, many epilepsy syndromes are characterised by a
high frequency of seizures. Further, many AEDs have a
high rate of clearance in this age group. Indeed, a rela-
tively high seizure frequency may preclude recruitment in
view of the concern about a 2-week baseline. Our pilot
data from previous trials and continuing work in our KD
research clinics strongly suggest that seizure response to
either the KD or usual AEDs is determined in the infant
population by 4 weeks. Previous AED studies in this age
group have also utilised a 1-day to 4-week titration period
and a 4-day to 4-week stabilisation period [38–40]. The
balance is between the likely time required to determine
failure of the AED and the time required to establish a
child on the KD. Eight weeks allows a 4–6 week titration
for establishing the KD or an AED, with at least 2 weeks’
stability for seizure assessment.
Trial Management Group
Membership






 The Trial Management Group (TMG) has been
established by the chief investigator (CI) as part of
the trial design to monitor the conduct and progress
of the trial
 The TMG will also ensure that the researchers have
access to documentation necessary for the conduct
of the trial and monitor data to identify unusual
patterns
 Monthly update of AEs occurring at each site will be
reviewed. If unexpected events occur in either of the
arms, these are to be reported to the sponsor
 The TMG will assess and confirm the decision to
progress to the full trial from pilot study completion
at two centres, as per protocol
 The TMG will meet monthly at the start of the
study and then quarterly on completion of
recruitment
 The quorum for the TMG will be four members.
This should include the chief investigator, two
members plus the trial statistician
 The TMG meetings will be minuted and a copy of
the minutes will be held in the TMG. A copy signed
by the CI will be sent to the sponsor for oversight
(or the CI will be included in the email copy to the
sponsor)
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Trial Steering Committee
Membership
The Committee will be made up of the following:
 Independent chair
 Chief investigator
 Clinical trial manager
 Two parent representatives
 Principal investigators
 Two independent members






 The Trial Steering Committee (TSC) has been
established by the CI as part of the trial design, to
assess at intervals the progress of the trial, the safety
data and the critical efficacy endpoints
 The TSC will recommend to the sponsor whether to
continue, amend or stop the trial. The TSC will
review the AE logs and Case Report Forms (CRFs)
in line with the approved protocol
 The TSC will meet twice a year to review the safety
data and efficacy endpoints captured in the trial
database
 The quorum for the TSC will be four members. This
should include the CI, two members plus a
representative from the CTU
 Representatives of the trial sponsor and the trial
funder will be invited to all TSC meetings
 The TSC will be responsible for approving all formal
interim analyses of the data prior to external
presentation or submission for publication
 The TSC meetings will be minuted and a copy of
the minutes will be held in the TMF and a copy
signed by the CI will be sent to the sponsor for
oversight (or the CI will be included in the email
copy to the sponsor)
 To protect patient confidentiality, trial participants’
identities and any identifiers, such as names and
hospital numbers, will be removed
Data Monitoring Committee
Membership
The Committee will be made up of the following:





 It is the only body involved in a trial that has access
to the unblinded comparative data
 The role of its members is to monitor these data
and make recommendations to the TSC on whether
there any ethical or safety reasons why the trial
should not continue
 The safety, rights and wellbeing of the trial
participants are paramount
 The Data Monitoring Committee (DMC) considers
the need for any interim analysis advising the TSC
regarding the release of data and/or information
 The DMC may be asked by the TSC, trial sponsor
or trial funder to consider data emerging from other
related studies
 Membership of the DMC should be completely
independent, small (three to four members) and
comprise experts in the field, such as a clinician
with experience in the relevant area and an expert
trial statistician
 Responsibility for calling and organising DMC
meetings lies with the CI, in association with the
chair of the DMC. The project team should provide
the DMC with a comprehensive report, the content
of which should be agreed in advance by the chair
of the DMC
 The DMC should meet at least annually, or more
often as appropriate, and meetings should be timed
so that reports can be fed into the TSC
Trial status
The trial was initiated in the pilot phase on 1 February
2015 and is currently recruiting in the full trial phase
across nine centres. We are in the process of initiating
further centres as part of the next amendment. Twenty-
nine patients have been randomised to date and the
planned recruitment end date is July 2018.
Additional files
Additional file 1: Schematic of trial design. (DOCX 71 kb)
Additional file 2: Treatment Side Effects Questionnaire. (DOCX 14 kb)
Additional file 3: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. Shows the recommended
items to address in a clinical trial protocol and related documents in
accordance with the SPIRIT 2013 template. This includes a template parental
Consent Form, Patient Information Sheet and GP Letter. (PDF 326 kb)
Additional file 4: (AED consensus flowchart). (DOCX 44 kb)
Additional file 5: Names and descriptions of investigational medicinal
products used in KIWE. (DOCX 15 kb)
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